Becton, Dickinson And Company (NYSE:BDX) Valuation According To Analysts

(NEO). A frequently used tool among technical stock analysts is the moving average. JPMorgan Chase & Co. lowered Becton Dickinson and from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $190.00 to $175.00 in a research note on Tuesday, January 3rd. Zacks Investment Research upgraded shares of Becton Dickinson and from a hold rating to a buy rating and set a $206.00 target price on the stock in a report on Tuesday, April 11th.

During the latest trading session Becton, Dickinson and Company (NYSE:BDX) stock went up with a prior 52-week high of $186.40.During the session shares traded on above-average volume.

Among 7 analysts covering Mentor Graphics (NASDAQ:MENT), 1 have Buy rating, 1 Sell and 5 Hold. The stock presently has a consensus rating of Buy and an average target price of $186.09.

Becton, Dickinson and Company (BDX) reported sales (ttm) of 12.42 Billion, whereas, 13 number of analysts estimated the mean sale of 2924.66 million. Sequoia Fincl Advisors holds 0.04% of its portfolio in Becton Dickinson and Co (NYSE:BDX) for 1,797 shares. However the price at the close of last session was -2.04% lower than its 50-day moving average and 2.75% over its 200-day moving average.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, February 2nd. The medical instruments supplier reported $2.33 earnings per share for the quarter, topping the consensus estimate of $2.11 by $0.22. On the other side, analysts now consider Becton, Dickinson and Company a neutral, and a technical analysis of the stock is setting somewhat neutral outlook for now.

The company’s expected revenue in the current quarter to be 2.93 Billion, seeing a projected current quarter growth of 2.8%, and per annum growth estimates over the next 5 year period of around 10.21%. The Jensen Investment Management Inc holds 2.46 million shares with $406.83 million value, up from 2.26 million last quarter. On average, analysts predict that Becton Dickinson and will post $9.44 earnings per share for the current fiscal year. New Mexico Educational Retirement Board has invested 0.17% in Becton Dickinson and Co (NYSE:BDX). The legal version of this report can be read at https://www.com-unik.info/2017/04/28/becton-dickinson-and-co-bdx-receives-hold-rating-from-royal-bank-of-canada-updated.html.

In other Becton Dickinson and news, VP Jeffrey S. Sherman sold 31,464 shares of the business’s stock in a transaction dated Wednesday, February 15th.

The stock grew about 12.34% in the past 5 years, this positive value indicates that the stock constantly performed well in previous years as well. Following the completion of the transaction, the vice president now directly owns 22,094 shares of the company’s stock, valued at approximately $3,977,361.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Several institutional investors have recently made changes to their positions in the stock. Finally, BlackRock Investment Management LLC raised its position in Becton Dickinson and by 30.4% in the third quarter. HL Financial Services LLC raised its stake in Becton Dickinson and by 20.3% in the third quarter. Cribstone Capital Management LLC now owns 874 shares of the medical instruments supplier’s stock valued at $161,000 after buying an additional 666 shares in the last quarter. Norris Perne & French LLP MI raised its position in shares of Becton Dickinson and by 3.6% in the third quarter. WASHINGTON TRUST Co now owns 93,600 shares of the medical instruments supplier’s stock worth $16,823,000 after buying an additional 55,896 shares in the last quarter. Finally, Argentus Capital Management LLC purchased a new position in Becton Dickinson and during the third quarter worth approximately $167,000. Glassman Wealth Services now owns 854 shares of the medical instruments supplier’s stock worth $141,000 after buying an additional 6 shares in the last quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in BDX.

Becton, Dickinson and Company is a global medical technology firm engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Firm operates through two divisions: BD Medical and BD Life Sciences. BD has almost 50,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health.

Leave a Reply

Your email address will not be published. Required fields are marked *